Lpez A, Ortiz F, Doerrier C, Venegas C, Fernndez-Ortiz M, Aranda P, Acua-Castroviejo D (2017) Mitochondrial impairment and melatonin protection in parkinsonian mice do not depend of inducible or neuronal nitric oxide synthases
However, GLP-1 therapy can unmask or worsen pre-existing androgenic alopecia through hormonal changes associated with fat loss, particularly in women over 40
dose escalation may be delayed by 1 additional week if necessary: Week 1: Inject 0.6 mg subcutaneously once a day Week 2: Inject 1.2 mg subcutaneously once a day Week 3: Inject 1.8 mg subcutaneously once a day Week 4: Inject 2.4 mg subcutaneously once a day Week 5: Inject 3 mg subcutaneously once a day Maintenance dose : 3 mg subcutaneously once a day-If maintenance dose is not tolerated, discontinuation is recommended
We conducted one of the largest real world studies on GLP-1 usage and effectiveness
What that looks like in practice is straightforward